Asset Type: Media article

Pacific Biosciences’ technology may finally fulfill the dream of gene sequencing.

National Biotechnology Editor Luke Timmerman visited PacBio as the company prepared for commercial shipping.

By making its SMRT Analysis suite available under an open source license, the company hopes to “accelerate the development of software and informatics tools for third-generation sequence data.”

Can Eric Schadt and the PacBio team help change the way we view biology?

Genomics startups like PacBio are helping to reshape the pharmaceutical sector and other industries from agriculture to energy.

PacBio made the TR50 list of most innovative companies, recognized for contributions to advancing in pathogen detection.

MedTech Executive interviewed PacBio CEO Hugh Martin about his leadership and the launch of the PacBio RS.

CSO Dr. Eric Schadt penned this perspectives piece for the 10th Anniversary of the Human Genome Publication.

Several early-access users of the PacBio RS reported at AGBT how the single-molecule real-time sequencing technology has been performing in their hands.

Pacific Biosciences has partnered with 13 more companies and organizations on products and services upstream and downstream of its sequencing platform.

CSO Dr. Eric Schadt discusses the recent project to rapidly sequence the Haitian cholera pathogen.

Hugh Martin demonstrates why full disclosure doesn’t have to be bad for business.

Pacific Biosciences of California Inc. has developed equipment that is expected to cut DNA sequencing from an average of 10 days to minutes.

In a dramatic piece of ultra-quick genetic detective work, next-generation sequencing company Pacific Biosciences has decoded the sequence of the strain of bacteria responsible for the deadly cholera outbreak in Haiti.

The Gold honor was awarded to Pacific Biosciences, for its breakthrough product PacBio RS, which enables single molecule, real-time, or SMRT, detection of biological processes, for the first time.